The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins

Importance of the field: The ABCG2 efflux transporter is expressed in multiple tissues and plays an important role in the disposition of many statins. The functional 421C>A polymorphism in ABCG2 that reduces transporter activity has been found to be associated with increased systemic exposures to certain statins. Areas covered in this review: We review and evaluate the associations of the ABCG2 polymorphism on the pharmacokinetics and clinical efficacy of statins. What the reader will gain: This article gives a detailed overview of the ABCG2 transporter and extensively reviews its relations with the pharmacokinetics and lipid-lowering effects of statins. This review also discusses the potential role of the ABCG2 polymorphism in the clinical outcomes in statin-treated patients and statin–drug interactions. Take home message: The impact of the ABCG2 421C>A polymorphism on the disposition of the statins varies between different drugs and the effect on systemic exposure was greater in the case of rosuvastatin than other statins. This genetic variant was associated with greater low-density lipoprotein cholesterol response to rosuvastatin in Chinese and caucasian patients. The effect of the ABCG2 421C>A polymorphism on the lipid response to other substrate statins and clinical outcomes need to be evaluated in future studies.

[1]  T. Fojo,et al.  Amplification of 4q21–q22 and the MXR gene in independently derived mitoxantrone‐resistant cell lines , 2000, Genes, chromosomes & cancer.

[2]  A. V. van Herwaarden,et al.  Sex-Dependent Expression and Activity of the ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (BCRP/ABCG2) in Liver , 2005, Molecular Pharmacology.

[3]  K. Maeda,et al.  SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.

[4]  M. Hirata,et al.  Impact of cholesterol on ABC and SLC transporters expression and function and its role in disposition variability to lipid-lowering drugs. , 2009, Pharmacogenomics.

[5]  J. Schellens,et al.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. , 2002, Molecular cancer therapeutics.

[6]  Qingcheng Mao,et al.  Role of the breast cancer resistance protein (ABCG2) in drug transport , 2005, The AAPS Journal.

[7]  P. Neuvonen,et al.  Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. , 2009, Pharmacogenomics.

[8]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  H. Melhus,et al.  Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. , 2001, The Journal of pharmacology and experimental therapeutics.

[10]  P. Leung,et al.  Progesterone Receptor (PR) Isoforms PRA and PRB Differentially Regulate Expression of the Breast Cancer Resistance Protein in Human Placental Choriocarcinoma BeWo Cells , 2008, Molecular Pharmacology.

[11]  E. Schuetz,et al.  Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. , 2003, Pharmacogenetics.

[12]  J. Schuetz,et al.  The Stem Cell Marker Bcrp/ABCG2 Enhances Hypoxic Cell Survival through Interactions with Heme* , 2004, Journal of Biological Chemistry.

[13]  S. Fujimori,et al.  Effects of Three Strong Statins (Atorvastatin, Pitavastatin, and Rosuvastatin) on Serum Uric Acid Levels in Dyslipidemic Patients , 2010, Nucleosides, nucleotides & nucleic acids.

[14]  W. T. Beck,et al.  Identification of a Novel Estrogen Response Element in the Breast Cancer Resistance Protein (ABCG2) Gene , 2004, Cancer Research.

[15]  B. Tomlinson,et al.  Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients , 2010, Pharmacogenetics and genomics.

[16]  C. Beglinger,et al.  Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. , 2005, Biochemical pharmacology.

[17]  T. Litman,et al.  A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). , 2001, Biochimica et biophysica acta.

[18]  L. Lue,et al.  ABCG2 Is Upregulated in Alzheimer's Brain with Cerebral Amyloid Angiopathy and May Act as a Gatekeeper at the Blood–Brain Barrier for Aβ1–40 Peptides , 2009, The Journal of Neuroscience.

[19]  S. Bates,et al.  Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib , 2010, Drug Metabolism and Disposition.

[20]  H. Kotani,et al.  Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2 , 2004, International journal of cancer.

[21]  G. Raman,et al.  APOE gene polymorphisms and response to statin therapy , 2009, The Pharmacogenomics Journal.

[22]  M. Gottesman,et al.  Overview: ABC Transporters and Human Disease , 2001, Journal of bioenergetics and biomembranes.

[23]  B. Rovin,et al.  Uric acid and cardiovascular risk. , 2009, The New England journal of medicine.

[24]  T. Litman,et al.  Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.

[25]  N. de Las Heras,et al.  Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. , 2007, Current Medicinal Chemistry.

[26]  P. Neuvonen,et al.  Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2007, Clinical pharmacology and therapeutics.

[27]  W. Haefeli,et al.  Interaction of angiotensin receptor type 1 blockers with ATP‐binding cassette transporters , 2010, Biopharmaceutics & drug disposition.

[28]  Y. Sugiyama,et al.  Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs , 2009, Expert opinion on drug metabolism & toxicology.

[29]  J. Huse,et al.  The ABCG2 resistance network of glioblastoma , 2009, Cell cycle.

[30]  C. Gieger,et al.  Genomewide association analysis of coronary artery disease. , 2007, The New England journal of medicine.

[31]  Deborah A Nickerson,et al.  Variation in the 3-Hydroxyl-3-Methylglutaryl Coenzyme A Reductase Gene Is Associated With Racial Differences in Low-Density Lipoprotein Cholesterol Response to Simvastatin Treatment , 2008, Circulation.

[32]  Y. Sugiyama,et al.  Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[33]  A. Hofman,et al.  Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study , 2008, The Lancet.

[34]  W. Roberts.  The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. , 1997, The American journal of cardiology.

[35]  R. Kim,et al.  Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants , 2007, Pharmacogenetics and genomics.

[36]  H. Fujino,et al.  Transporter‐mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG‐CoA reductase , 2005, The Journal of pharmacy and pharmacology.

[37]  P. Neuvonen,et al.  ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2009, Clinical pharmacology and therapeutics.

[38]  Soojin Park,et al.  Effect of Silymarin Supplement on the Pharmacokinetics of Rosuvastatin , 2008, Pharmaceutical Research.

[39]  Vasilis Vasiliou,et al.  Human ATP-binding cassette (ABC) transporter family , 2009, Human Genomics.

[40]  Caroline A. Lee,et al.  Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment , 2005, Clinical pharmacology and therapeutics.

[41]  J. Fleg,et al.  Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. , 2008, JAMA.

[42]  R. Assoian,et al.  ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition. , 2008, Cancer research.

[43]  H. Milionis,et al.  Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. , 2004, American heart journal.

[44]  M. Morris,et al.  Effects of the Flavonoid Chrysin on Nitrofurantoin Pharmacokinetics in Rats: Potential Involvement of ABCG2 , 2007, Drug Metabolism and Disposition.

[45]  A. Sparreboom,et al.  Pharmacogenomic importance of ABCG2. , 2008, Pharmacogenomics.

[46]  Masahiko Watanabe,et al.  Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte‐derived soluble factor(s) , 2004, Journal of neurochemistry.

[47]  Kazuya Maeda,et al.  Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer R , 2005, Journal of Pharmacology and Experimental Therapeutics.

[48]  T. Litman,et al.  Regulation of ABCG2 Expression at the 3′ Untranslated Region of Its mRNA through Modulation of Transcript Stability and Protein Translation by a Putative MicroRNA in the S1 Colon Cancer Cell Line , 2008, Molecular and Cellular Biology.

[49]  Thomas Ried,et al.  Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2 , 2009, Molecular Cancer Therapeutics.

[50]  Marilyn E Morris,et al.  MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells , 2009, Molecular Pharmacology.

[51]  B. Tomlinson,et al.  ABCG2 Polymorphism Is Associated With the Low‐Density Lipoprotein Cholesterol Response to Rosuvastatin , 2010, Clinical pharmacology and therapeutics.

[52]  W. Haefeli,et al.  Localization of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) in Lipid Rafts/Caveolae and Modulation of Its Activity by Cholesterol in Vitro , 2007, Journal of Pharmacology and Experimental Therapeutics.

[53]  P. Boutros,et al.  Aryl Hydrocarbon Receptor Is a Transcriptional Activator of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) , 2010, Molecular Pharmacology.

[54]  R. Collins,et al.  Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths , 2007, The Lancet.

[55]  M. Morris,et al.  EFFECTS OF DIHYDROPYRIDINES AND PYRIDINES ON MULTIDRUG RESISTANCE MEDIATED BY BREAST CANCER RESISTANCE PROTEIN: IN VITRO AND IN VIVO STUDIES , 2005, Drug Metabolism and Disposition.

[56]  E. Schaefer,et al.  Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. , 2004, Atherosclerosis.

[57]  R. Shamburek,et al.  The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. , 2009, Atherosclerosis.

[58]  M. Barrand,et al.  Localisation of breast cancer resistance protein in microvessel endothelium of human brain , 2002, Neuroreport.

[59]  S. Bates,et al.  ABCG2: a perspective. , 2009, Advanced drug delivery reviews.

[60]  M. Niemi.  Transporter Pharmacogenetics and Statin Toxicity , 2010, Clinical pharmacology and therapeutics.

[61]  G. Schmitz,et al.  Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy , 2007, Current opinion in lipidology.

[62]  A. Pardee.  Role Reversal for Anticancer Agents , 2002, Cancer biology & therapy.

[63]  A. Marian,et al.  Pharmacogenetic study of statin therapy and cholesterol reduction. , 2005, Current atherosclerosis reports.

[64]  P. Neuvonen,et al.  ABCB1 Haplotypes Differentially Affect the Pharmacokinetics of the Acid and Lactone Forms of Simvastatin and Atorvastatin , 2008, Clinical pharmacology and therapeutics.

[65]  S. Grimm,et al.  ATP-DEPENDENT TRANSPORT OF ROSUVASTATIN IN MEMBRANE VESICLES EXPRESSING BREAST CANCER RESISTANCE PROTEIN , 2006, Drug Metabolism and Disposition.

[66]  Y. Sugiyama,et al.  Functional Analysis of SNPs Variants of BCRP/ABCG2 , 2004, Pharmaceutical Research.

[67]  S. Bates,et al.  Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure , 2007, Molecular Cancer Therapeutics.

[68]  Yi Wang,et al.  Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin , 2008, Drug Metabolism and Disposition.

[69]  E. Barta,et al.  Peroxisome Proliferator-activated Receptor γ-regulated ABCG2 Expression Confers Cytoprotection to Human Dendritic Cells* , 2006, Journal of Biological Chemistry.

[70]  M. J. van de Vijver,et al.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.

[71]  Vincenzo,et al.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.

[72]  I. Cascorbi,et al.  Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. , 2006, Pharmacology & therapeutics.

[73]  T. Litman,et al.  Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. , 2006, Cancer letters.

[74]  E. Barta,et al.  Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. , 2006, The Journal of biological chemistry.

[75]  Y. Miki,et al.  C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. , 2002, Molecular cancer therapeutics.

[76]  P. Neuvonen,et al.  No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. , 2009, British journal of clinical pharmacology.

[77]  Dongmei Meng,et al.  Genetic analysis of ABCG2 gene C421A polymorphism with gout disease in Chinese Han male population , 2010, Human Genetics.

[78]  S. Bates,et al.  Single nucleotide polymorphisms modify the transporter activity of ABCG2 , 2005, Cancer Chemotherapy and Pharmacology.

[79]  No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG‐CoA Reductase Inhibitor , 2002, Journal of clinical pharmacology.

[80]  Mark M. Roden,et al.  Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein , 1999, Pharmaceutical Research.

[81]  T. Ishikawa,et al.  In vitro evaluation of photosensitivity risk related to genetic polymorphisms of human ABC transporter ABCG2 and inhibition by drugs. , 2007, Drug metabolism and pharmacokinetics.

[82]  S. Bates,et al.  ABCG2: structure, function and role in drug response. , 2008, Expert opinion on drug metabolism & toxicology.

[83]  L. Szente,et al.  Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. , 2007, Biochimica et biophysica acta.

[84]  R. Rosenson.  Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia , 2003, Expert review of cardiovascular therapy.

[85]  Julia Qiu,et al.  Interactions of Human P-glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin , 2004, Pharmaceutical Research.

[86]  P. Neuvonen,et al.  SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin , 2006, Clinical pharmacology and therapeutics.

[87]  G. Kéri,et al.  High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. , 2004, Molecular pharmacology.

[88]  L. Doyle,et al.  Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. , 2001, Biochimica et biophysica acta.

[89]  B. Schreurs.  The effects of cholesterol on learning and memory , 2010, Neuroscience & Biobehavioral Reviews.

[90]  Yuichi Sugiyama,et al.  Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. , 2006, Pharmacology & therapeutics.

[91]  J. Keelan,et al.  Independent Regulation of Apical and Basolateral Drug Transporter Expression and Function in Placental Trophoblasts by Cytokines, Steroids, and Growth Factors , 2007, Drug Metabolism and Disposition.

[92]  M. Waye,et al.  Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease , 2009 .

[93]  Balázs Sarkadi,et al.  Ins and outs of the ABCG2 multidrug transporter: an update on in vitro functional assays. , 2009, Advanced drug delivery reviews.

[94]  Shaoxiang Zhang,et al.  MicroRNAs play a role in the development of human hematopoietic stem cells , 2008, Journal of cellular biochemistry.

[95]  S. Bates,et al.  Single-Nucleotide Polymorphism (SNP) Analysis in the ABC Half-Transporter ABCG2 (MXR/BCRP/ABCP1) , 2002, Cancer biology & therapy.

[96]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[97]  M. Hirai,et al.  Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the induction of MDR1 expression and function in LS180 cells. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[98]  Mengmeng Wang.  Extending the good diet, good health paradigm: modulation of breast cancer resistance protein (BCRP) by flavonoids. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[99]  A. Peyer,et al.  HMG‐CoA reductase inhibitors and P‐glycoprotein modulation , 2001, British journal of pharmacology.

[100]  Alberto Piazza,et al.  Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants , 2009, Nature Genetics.

[101]  S. Bates,et al.  Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition , 2004, Cancer Research.

[102]  T. Ishikawa,et al.  Functional Validation of the Genetic Polymorphisms of Human ATP-Binding Cassette (ABC) Transporter ABCG2: Identification of Alleles That Are Defective in Porphyrin Transport , 2006, Molecular Pharmacology.

[103]  Mikko Niemi,et al.  SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid , 2006, Pharmacogenetics and genomics.

[104]  Ya-li Liu,et al.  Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[105]  P. Barter,et al.  Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). , 2010, The American journal of cardiology.

[106]  A. Rodrigues.  Efflux and uptake transporters as determinants of statin response , 2010, Expert opinion on drug metabolism & toxicology.

[107]  K. Maeda,et al.  Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin , 2005, Molecular Pharmacology.

[108]  N. Samani,et al.  Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial Infarction: The GEOSTAT-1 Study , 2010, Circulation. Cardiovascular genetics.